139209-26-0

Basic information

• Product Name: 4-Amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide
• Synonyms: 4-Amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;2'-beta-C-Methylsangivamycin
• CAS NO: 139209-26-0
• Molecular Formula: C13H17N5O5
• Molecular Weight: 323.30458
• Mol File: 139209-26-0.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide(139209-26-0)
• EPA Substance Registry System: 4-Amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide(139209-26-0)

Safety Data

• Hazardous Substances Data: 139209-26-0(Hazardous Substances Data)

Upstream product

• 141232-18-0 5-cyano-4-tritylaminopyrrolo<2,3-d>pyrimidine 
• 19393-83-0 4-amino-6-bromo-5-cyanopyrrolo[2,3-d]pyrimidine 
• 141232-24-8 4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 
• 114475-00-2 2,3-O-isopropylidene-2-C-tosyloxymethyl-5-O-trityl-α,β-D-ribofuranose 
• 141232-21-5 2,3-O-isopropylidene-2-C-methyl-5-O-trityl-D-ribofuranosyl chloride 
• 943638-31-1 2,3-O-isopropylidene-1-hydroxy-2-C-methyl-5-O-trityl-D-ribofuranose 
• 141232-17-9 6-bromo-5-cyano-4-tritylaminopyrrolo<2,3-d>pyrimidine 

Relevant articles and documents

Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.